The Market size of the Global AI-Enabled Drug Discovery and Clinical Trials market in the year 2021 is valued at 450.72 million and is predicted to reach 3641.01 million by the year 2030 at a 26.3% CAGR during the forecast period.

Curious about this latest version of report? Obtain Report Details @ https://www.insightaceanalytic.com/report/global-ai-enabled-drug-discovery-and-clinical-trials-market-/1239

AI-Enabled Drug Discovery and Clinical Trials are fundamental procedures primarily done by using artificial intelligence technology that has been gaining wide acceptance across the world. Increasing penetration of technology in the healthcare industry will further boost AI-Enabled Drug Discovery and Clinical Trials market potential in the long run. Digitization of the healthcare industry saw a significant boost in the COVID-19 pandemic, and this trend has created a lucrative setting for AI-Enabled Drug Discovery and Clinical Trials market growth throughout the forecast period. Increasing support from the government and rising demand for rapid development of drugs is expected to boost AI-Enabled Drug Discovery and Clinical Trials market potential. Human rights concerns associated with clinical trials are also a factor that increases the adoption of AI in clinical trials and drug discovery as they reduce the risk to human health. However, the high costs of deployment and operation of AI-Enabled Drug Discovery and Clinical Trials are projected to have a hampering effect on the global AI-Enabled Drug Discovery and Clinical Trials market potential through 2030. The rising establishment of multiple healthcare research companies will also favour AI-Enabled Drug Discovery and Clinical Trials market potential throughout the forecast period.

List of Prominent Players in the AI-Enabled Drug Discovery and Clinical Trials Market:

Accutar Biotechnology Inc.

AiCure

Ardigen

Atomwise Inc.

Benevolent AI

Berg

Berkeley Lights

BioAge Labs

Biovista

C4X Discovery Holdings Plc

Clinithink Ltd

Cloud Pharmaceuticals

Cyclica Inc.

CytoReason

Concerto Health AI.

Deep Genomics Inc.

DeepThink Health Inc.

Envisagenics, Inc.

Exscientia Limited

e-therapeutics plc

GNS Healthcare

Insilico Medicine

Lantern Pharma Inc.

Medable, Inc.

Mind the Byte

NuMedii, Inc

Nuritas, Ltd.

Owkin, Inc.

Recursion Pharmaceuticals, Inc.

Schrödinger, LLC

Symphony Innovation, LLC  

 TARA Biosystems, Inc.

twoXAR, Incorporated

Verge Analytics, Inc.

Winterlight Labs Inc.

WuXi Nextcode Genomics

XtalPi Inc.

Other Prominent Players

For More Information @ https://www.insightaceanalytic.com/report/global-ai-enabled-drug-discovery-and-clinical-trials-market-/1239

Market Dynamics:

Drivers:

The increasing prevalence of chronic diseases and augmented demand for better healthcare services is expected to drive AI-Enabled Drug Discovery and Clinical Trials market growth. Other factors such as increasing incidence of chronic diseases, rising research activity, growing support from the government, high healthcare expenditure, etc., are also expected to crucially sculpt AI-Enabled Drug Discovery and Clinical Trials market growth over the forecast period. The increasing digitization of the healthcare industry is also expected to drive AI-Enabled Drug Discovery and Clinical Trials market growth in the coming years.

Challenges:

The major challenge for AI-Enabled Drug Discovery and Clinical Trials market is to manage the deployment and operations cost of these new systems that will be very complex to use and maintain. The absence of a skilled workforce for the same is also anticipated to hinder the adoption of AI-Enabled Drug Discovery and Clinical Trials systems across the world. The companies in the AI-Enabled Drug Discovery and Clinical Trials market are expected to work on these challenges to unlock full growth potential over the coming years.

Regional Trends:

North America holds a considerable proportion of the global market for AI-Enabled Drug Discovery and Clinical Trials due to its quick adoption of innovative technology. This region’s market potential for AI-Enabled Drug Discovery and Clinical Trials will be driven through 2030 by the presence of developed healthcare infrastructure, a high level of healthcare research activity, and supporting government efforts. The United States is likely to be a very lucrative market in this area due to the increasing frequency of cancer and the necessity for earlier treatment. Additionally, high healthcare expenditures will play a significant function in this industry. The ageing population will also fuel the market potential for AI-Enabled Drug Discovery and Clinical Trials in the next years.

Recent Developments:

In May 2022, Standigm announced that it would be eyeing using its expertise to find a treatment for Crohn’s disease. With the help of AI, the company plans to produce new compounds to test for their treatment effects on multiple patients.

AI-Enabled Drug Discovery and Clinical Trials Market Segmentation:

AI-Enabled Drug Discovery and Clinical Trials Market Segmentation: By Component Estimates & Trend Analysis

  • Solutions
  • Services

AI-Enabled Drug Discovery and Clinical Trials Market Segmentation: By Application Estimates & Trend Analysis

  • Data Aggregation and Analysis
  • Clinical Trials
  • Drug Design
  • Drug Characterization
  • Biomarker Research

AI-Enabled Drug Discovery and Clinical Trials Market Segmentation: By Therapeutic Application Estimates & Trend Analysis

  • Oncology
  • Cardiovascular Diseases
  • Nervous System Diseases
  • Respiratory Disorder
  • Metabolic Diseases
  • Immunologic Diseases
  • Infectious Diseases

AI-Enabled Drug Discovery and Clinical Trials Market Segmentation: By End-user Estimates & Trend Analysis

  • Biopharmaceutical Industry
  • Contract Research Organizations (CROs)
  • Academic Institutes and Research Centers

Request for ToC/Proposal: https://www.insightaceanalytic.com/request-sample/1239

Tags: AI-Enabled Drug Discovery and Clinical Trials Market